Neurol. praxi. 2019;20(4):292-295 | DOI: 10.36290/neu.2019.130
A new era of multiple sclerosis treatment
- Neurologická klinika, LF UK a FN Plzeň
Multiple sclerosis is very serious neurological disease. If not treated it causes severe disability of patients. New hope in treating MS arose in the nineties due to arrival of modern therapy. However only last couple decades have brought revolutionary changes in the treatment of this disease. Besides medicaments used continuously to affect the disease, we now have new specific therapeutic group called immune reconstitution therapy (IRT), which can induce long-term remission of the disease without continual treatment. New highly efficient therapy changes our views of goals in therapy of MS. Now our main goal is to achieve long-term remission of the disease, which is defined by the concept of No Evidence of Disease Activity (NEDA).
Keywords: multiple sclerosis, maintenance/escalation therapy, immune reconstitution therapy, no evidence of disease activity (NEDA).
Published: September 1, 2019 Show citation
References
- Banwell B, Giovannoni G, Hawkes C, Lublin F. Editors' welcome and a working definition for a multiple sclerosis cure. Mult. Scler. Relat. Disord. 2013; 2: 65-67.
Go to original source... 
Go to PubMed... - Feinstein A, DeLuca J, Baune BT, Filippi M, Lassman H. Cognitive and neuropsychiatric disease manifestations in MS. Mult Scler Relat Disord. 2013; 2(1): 4-12. Go to original source... Go to PubMed...
- Giovannoni G. Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm. Curr Opin Neurol. 2018; 31(3): 233-243. Go to original source... Go to PubMed...
- Havrdova E. Roztroušená skleróza. Mladá fronta, 2013.
- Kobelt G, Berg J, Lindgren P, Fredrikson S, Jönsson B. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2006; 77(8): 918-926. Go to original source... Go to PubMed...
- Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983; 33(11): 1444-1452. Go to original source... Go to PubMed...
- Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol. 2005; 4(5): 281-288. Go to original source... Go to PubMed...
- Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018; 24(2): 96-120. Go to original source... Go to PubMed...
- Oksenberg JR, Baranzini SE, Hauser SL. Biological concepts of multiple sclerosis pathogenesis and relationship to treatment. In: Cohen JA, and Rudick RA, (eds), Multiple Sclerosis Therapeutics, 3rd edition. London: Informa Healthcare 2007: 23-44. Go to original source...
- Pfleger CC, Flachs EM, Koch-Henriksen N. Social consequences of multiple sclerosis: early pension and temporary unemployment - a historical prospective cohort study. Mult Scler. 2010; 16(1): 121-126. Go to original source... Go to PubMed...
- Torkildsen GN, Lie SA, Aarseth JH, Nyland H, Myhr KM. Survival and cause of death in multiple sclerosis: results from a 50year follow-up in Western Norway. Mult Scler. 2008; 14(9): 1191-1198. Go to original source... Go to PubMed...